ToolsCalculators
Indian Takayasu Clinical Activity Score (ITAS2010)
Assesses clinical disease activity in Takayasu arteritis from new or worsening features.
Indian Takayasu Clinical Activity Score (ITAS2010)
New or worsening fever attributable to Takayasu arteritis
New or worsening unintentional weight loss
New or worsening myalgia
New or worsening arthralgia or arthritis
New erythema nodosum-like skin lesions
New visual disturbance from retinal ischaemia (Takayasu retinopathy)
New vascular bruit
New pulse inequality
New pulse loss
New limb claudication
New carotidodynia
New cardiac failure
New valvular heart disease (e.g. aortic regurgitation)
New angina or myocardial ischaemia
New aneurysm or arterial dilatation
New abdominal pain from mesenteric ischaemia
New diastolic hypertension
New renal impairment or renal artery stenosis
New stroke
New seizure
New syncope
New dizziness or vertigo from vascular insufficiency
Result0 points
No new or worsening features in the last 3 months; disease appears clinically inactive.
When to use
- Assessing clinical activity of Takayasu arteritis based on new or worsening features over the preceding 3 months.
- Tracking disease activity over time or in response to immunosuppressive therapy.
Formula
Sum of new or worse (within the past 3 months) clinical features across systemic, cutaneous, ocular, cardiovascular, abdominal, renal, and neurological domains. Bruit, pulse inequality, pulse loss, claudication, carotidodynia, new diastolic hypertension, and stroke each score 2 points; all other features score 1 point.
Pearls and pitfalls
- This implementation covers the major validated domains and the documented weighting scheme (five cardiovascular items, one renal item, and one neurological item weighted at 2 points) rather than the full 44-item instrument used in the original publication; consult the original paper for the complete standardized item list used in formal trials.
- An acute-phase-reactant-adjusted variant (ITAS-A, adding 0-3 points for ESR/CRP) has also been described.